Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma Ads (NQ: ASND )

126.33 USD +1.52 (+1.22%)
Streaming Delayed Price Updated: 11:46 AM EDT, Apr 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,433
Open 125.00
Bid (Size) 126.24 (1)
Ask (Size) 126.48 (1)
Prev. Close 124.81
Today's Range 125.00 - 128.00
52wk Range 117.46 - 183.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum
From GlobeNewswire News Releases
Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021
Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism 
From GlobeNewswire News Releases

Performance

YTD
-23.66%
-23.66%
1 Month
-14.06%
-14.06%
3 Month
-27.07%
-27.07%
6 Month
-21.04%
-21.04%
1 Year
+3.29%
+3.29%

More News

Read More
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports Full Year 2020 Financial Results
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
From PR Newswire
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.